scholarly article | Q13442814 |
P50 | author | Ali Madian | Q86477587 |
P2093 | author name string | Satoshi Yamada | |
Hiroshi Nakase | |||
Minoru Matsuura | |||
Naoki Minami | |||
Takahiko Toyonaga | |||
Takuya Yoshino | |||
Yusuke Honzawa | |||
Yorimitsu Koshikawa | |||
P2860 | cites work | Inflammatory bowel disease: clinical aspects and established and evolving therapies | Q21957029 |
Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics | Q28338447 | ||
The mechanism of action of cyclosporin A and FK506 | Q30014847 | ||
Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study | Q34187731 | ||
Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up | Q34506976 | ||
Cytomegalovirus colitis complicating inflammatory bowel disease | Q34572006 | ||
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis | Q35768942 | ||
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications | Q36477912 | ||
Life-event stress induced by the Great East Japan Earthquake was associated with relapse in ulcerative colitis but not Crohn's disease: a retrospective cohort study | Q36649935 | ||
Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression | Q36671830 | ||
Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention | Q37789688 | ||
The pattern and outcome of acute severe colitis | Q37814560 | ||
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. | Q37964767 | ||
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis | Q38049777 | ||
Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. | Q38230163 | ||
Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis | Q40323292 | ||
Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis | Q41128447 | ||
Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus | Q41715872 | ||
Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus | Q43024877 | ||
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. | Q43328678 | ||
Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. | Q43497300 | ||
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis | Q43582796 | ||
Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients | Q43611596 | ||
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis | Q43798421 | ||
Response of refractory colitis to intravenous or oral tacrolimus (FK506). | Q44247090 | ||
Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis | Q44339242 | ||
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. | Q46543821 | ||
Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. | Q50891880 | ||
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 | ||
Cytomegalovirus infection in patients with ulcerative colitis diagnosed by quantitative real-time PCR analysis. | Q54590747 | ||
Management of acute severe ulcerative colitis | Q57265364 | ||
Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis | Q79631486 | ||
Management of acute severe colitis | Q79922499 | ||
Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies | Q81167677 | ||
Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus | Q86122542 | ||
P433 | issue | 1 | |
P921 | main subject | colitis | Q2453464 |
P304 | page(s) | e000021 | |
P577 | publication date | 2015-02-20 | |
P1433 | published in | BMJ open gastroenterology | Q27726654 |
P1476 | title | Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study | |
P478 | volume | 2 |
Q48853070 | ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. |
Q97905242 | Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients |
Q50097248 | Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. |
Q26766101 | Cytomegalovirus and ulcerative colitis: Place of antiviral therapy |
Q36317757 | EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. |
Q91729762 | Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial |
Q38662186 | Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. |
Q58788974 | Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis |
Q39041028 | Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study |
Q37338586 | Sleep disturbances in Japanese patients with inflammatory bowel disease and their impact on disease flare |
Q26997361 | Tacrolimus for the Treatment of Ulcerative Colitis |
Q91645954 | The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor |
Q39586257 | Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul |
Search more.